Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CD4 as AIDS trials endpoint

Executive Summary

Role of CD4 will be addressed along with other laboratory markers as indicators of clinical benefit at the Anti-Viral Drugs Advisory Committee meeting scheduled for Feb. 13. On Feb. 14, the committee will examine follow-up trials of Burrough Wellcome's Retrovir (zidovudine) in patients with moderately symptomatic and asymptomatic diseases. Meeting will be held at Holiday Inn Crowne Plaza, Plaza II Room, Rockville, Maryland, beginning at 8:30 a.m. both days.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS018614

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel